Replimune Group, Inc. - Common Stock (REPL)

Let's have a look at what is happening on the US markets one hour before the close of the markets on Wednesday. Below you can find the top gainers and losers in today's session.

Let's have a look at what is happening on the US markets on Wednesday. Below you can find the most active stocks in today's session.

Prasad stepped down as the Director of the Center for Biologics Evaluation and Research (CBER) on Tuesday, nearly three months into the job.

Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down.

As we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.

Wondering how the US markets performed one hour before the close of the markets on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.

The company had lined up a priority review in the hopes of winning an accelerated approval for its melanoma treatment.

Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session.

The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Replimune stock fell after the FDA rejected its RP1 application, citing flaws in the trial design and lack of substantial evidence for approval.